The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca / Merck & Co.), Zejula (GlaxoSmithKline), and Rubraca (Clovis Oncology). In November 2022, Elahere (ImmunoGen) entered the U.S. market as the first antibody-drug conjugate for patients with folate receptor alpha (FRα)-positive tumors. The late-phase pipeline for ovarian cancer is rapidly evolving. Novel drugs with a variety of mechanisms of action are set to launch for ovarian cancer and further diversify treatment options.
Questions answered
What is the size of the clinically and commercially relevant drug-treatable ovarian cancer population, and how will drug-treatment rates change over time?
What is the current treatment landscape for ovarian cancer? What are interviewed experts’ insights on current therapies?
What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?
What are the main drivers of and constraints in the treatment of ovarian cancer, and how will this market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Market share of drug classes for ovarian cancer: 2022
Market share of drug classes for ovarian cancer: 2032
Drug-treatable population share and major-market sales share in ovarian cancer: 2022
Drug-treatable population share and major-market sales share in ovarian cancer: 2032
Population positioning of therapies in ovarian cancer: United States
Population positioning of therapies in ovarian cancer: Europe
Population positioning of therapies in ovarian cancer: Japan
Ovarian cancer SWOT analysis
Market drivers and constraints
What factors are driving the market for ovarian cancer?
What factors are constraining the market for ovarian cancer?
Major-market sales for ovarian cancer by region: 2022-2032
Major-market sales for ovarian cancer by drug class: 2022-2032
Major-market sales of targeted therapies in the ovarian cancer market: 2022-2032
Major-market sales of PARP inhibitors by patient population: 2022-2032
Segment-specific trends
Patient-share dynamics of key therapies (excluding maintenance) in first-line advanced-stage ovarian cancer in the United States: 2022-2032
Patient-share dynamics of maintenance therapies in first-line advanced-stage ovarian cancer in the United States: 2022-2032
Patient-share dynamics of key therapies excluding maintenance treatments in the second-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
Patient-share dynamics of maintenance therapies in the second-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
Patient-share dynamics of key therapies excluding maintenance treatments in the third-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
Patient-share dynamics of maintenance therapies in the third-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
Patient-share dynamics of second-line platinum-resistant and platinum-refractory ovarian cancer in the United States: 2022-2032
Patient-share dynamics of third-line platinum-resistant and platinum-refractory ovarian cancer in the United States: 2022-2032
Patient-share dynamics of key therapies in the fourth- and subsequent-line ovarian cancer setting in the United States: 2022-2032
Forecast
Market Forecast Assumptions
Market Forecast Dashboard
Etiology and Pathophysiology
Disease overview
Disease pathophysiology
Disease pathogenesis
Disease classification
Ovarian cancer histologies
Molecular subtypes and key pathways
Screening tests: CA-125
Staging and classification
Staging and grading
International Federation of Gynecology and Obstetrics staging system for cancer of the ovary, fallopian tube, and peritoneum
Stage I-II
Stage III-IV
Key pathways and drug targets
Key pathways and drug targets in ovarian cancer
Key signaling pathways in epithelial cells
PARP inhibition: mechanism of action
Folate receptor pathway
Immune checkpoint inhibitors and modulators
Epidemiology
Key findings
Epidemiology populations
Disease definition, methods, and sources used
Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancers: 2022-2032
Disease definition, methods, and sources used
Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer by stage: 2022-2032
Disease definition, methods, and sources used
Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer by BRCA mutation: 2022-2032
Disease definition, methods, and sources used
Recurrent incident cases of epithelial ovarian and fallopian tube cancer: 2022-2032
Ovarian cancer patient flow
Drug-treatable cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer: 2022-2032
Drug-treated cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer: 2022-2032
Current Treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for ovarian cancer
Key current therapies
Overview
Mechanism of action of key current drug classes used for ovarian cancer
Current treatments used for ovarian cancer
Market events impacting the use of key current therapies in ovarian cancer
Key results from select clinical trials investigating bevacizumab for the treatment of ovarian cancer
Ongoing clinical development of bevacizumab
Expert insight: bevacizumab
Key results from select clinical trials investigating Lynparza for the treatment of ovarian cancer
Ongoing clinical development of Lynparza
Key ongoing clinical trials of Lynparza in the treatment of ovarian cancer
Expert insight: Lynparza
Key results from select clinical trials investigating Rubraca for the treatment of ovarian cancer
Ongoing clinical development of Rubraca
Key ongoing clinical trials investigating Rubraca in the treatment of ovarian cancer
Expert insight: Rubraca
Key results from select clinical trials investigating Zejula for the treatment of ovarian cancer
Ongoing clinical development of Zejula
Key ongoing clinical trials investigating Zejula in the treatment of ovarian cancer
Expert insight: Zejula
Key results of select clinical trials investigating Elahere for the treatment of ovarian cancer
Ongoing clinical development of Elahere
Key ongoing clinical trials of Elahere in the treatment of ovarian cancer
Expert insight: Elahere
Key results from select clinical trials investigating Yondelis for the treatment of ovarian cancer
Ongoing clinical development of Yondelis
Key results of select clinical trials investigating Mekinist for the treatment of ovarian cancer
Ongoing clinical development of Mekinist
Expert insight: Mekinist
Medical practice
Early-stage first-line ovarian cancer
Advanced-stage first-line ovarian cancer
Second- and third-line platinum-sensitive ovarian cancer
Second- and third-line platinum-resistant and -refractory ovarian cancer
Fourth- and subsequent-line ovarian cancer
Country-specific ovarian cancer treatment guidelines
Patient characteristics influencing drug selection in ovarian cancer
Treatment decision tree for early- and advanced-stage ovarian cancer: United States
Treatment decision tree for early- and advanced-stage ovarian cancer: Europe
Treatment decision tree for early- and advanced-stage ovarian cancer: Japan
Unmet Need Overview
Current and future attainment of unmet needs in ovarian cancer
Top unmet needs in ovarian cancer: current and future attainment
Drug Pipeline
Pipeline
Regulatory Milestones
Indication Comparison
Emerging Therapies
Key findings
Key emerging therapies
Key therapies in development for ovarian cancer
Estimated market authorization dates of key emerging therapies for the treatment of ovarian cancer
Key results of select clinical trials investigating Tecentriq for the treatment of ovarian cancer
Key ongoing clinical trials of Tecentriq in the treatment of ovarian cancer
Analysis of the clinical development program for Tecentriq
Expert insight: Tecentriq
Expectations for market authorization and sales opportunity of Tecentriq in ovarian cancer
Key results of select clinical trials investigating Keytruda for the treatment of ovarian cancer
Key ongoing clinical trials of Keytruda in the treatment of ovarian cancer
Analysis of the clinical development program for Keytruda
Expert insight: Keytruda
Expectations for market authorization and sales opportunity of Keytruda in ovarian cancer
Key results of select clinical trials investigating Opdivo for the treatment of ovarian cancer
Key ongoing clinical trials of Opdivo in the treatment of ovarian cancer
Analysis of the clinical development program for Opdivo
Expert insight: Opdivo
Expectations for market authorization and sales opportunity of Opdivo in ovarian cancer
Key results of select clinical trials investigating Imfinzi for the treatment of ovarian cancer
Analysis of the clinical development program for Imfinzi
Expert insight: Imfinzi
Expectations for market authorization and sales opportunity of Imfinzi in ovarian cancer
Key results of select clinical trials investigating Jemperli for the treatment of ovarian cancer
Key ongoing clinical trials of Jemperli in the treatment of ovarian cancer
Analysis of the clinical development program for Jemperli
Expert insight: Jemperli
Expectations for market authorization and sales opportunity of Jemperli in ovarian cancer
Key results of select clinical trials investigating olvimulogene nanivacirepvec for the treatment of ovarian cancer
Key ongoing clinical trials of olvimulogene nanivacirepvec in the treatment of ovarian cancer
Analysis of the clinical development program for olvimulogene nanivacirepvec
Expectations for market authorization and sales opportunity of olvimulogene nanivacirepvec in ovarian cancer
Key results of select clinical trials investigating relacorilant for the treatment of ovarian cancer
Key ongoing clinical trials of relacorilant in the treatment of ovarian cancer
Analysis of the clinical development program for relacorilant
Expert insight: relacorilant
Expectations for market authorization and sales opportunity of relacorilant in ovarian cancer
Key results of select clinical trials investigating oregovomab for the treatment of ovarian cancer
Key ongoing clinical trials of oregovomab in the treatment of ovarian cancer
Analysis of the clinical development program for oregovomab
Expert insight: oregovomab
Expectations for market authorization and sales opportunity of oregovomab in ovarian cancer
Key results of select clinical trials investigating Piqray for the treatment of ovarian cancer
Key ongoing clinical trials of Piqray in the treatment of ovarian cancer
Analysis of the clinical development program for Piqray
Expert insight: Piqray
Expectations for market authorization and sales opportunity of Piqray in ovarian cancer
Key results of select clinical trials investigating batiraxcept for the treatment of ovarian cancer
Analysis of the clinical development program for batiraxcept
Expert insight: batiraxcept
Expectations for market authorization and sales opportunity of batiraxcept in ovarian cancer
Key ongoing clinical trials of nemvaleukin alfa in the treatment of ovarian cancer
Analysis of the clinical development program for nemvaleukin alfa
Expert insight: nemvaleukin alfa
Expectations for market authorization and sales opportunity of nemvaleukin alfa in ovarian cancer
Key results of select clinical trials investigating upifitamab rilsodotin for the treatment of ovarian cancer
Key ongoing clinical trials of upifitamab rilsodotin in the treatment of ovarian cancer
Analysis of the clinical development program for upifitamab rilsodotin
Expert insight: upifitamab rilsodotin
Expectations for market authorization and sales opportunity of upifitamab rilsodotin in ovarian cancer
Key results of select clinical trials investigating navicixizumab for the treatment of ovarian cancer
Key ongoing clinical trials of navicixizumab in the treatment of ovarian cancer
Analysis of the clinical development program for navicixizumab
Expert insight: navicixizumab
Expectations for market authorization and sales opportunity of navicixizumab in ovarian cancer
Early-phase pipeline analysis
Select compounds in Phase 1/2 development for ovarian cancer
Access and Reimbursement Overview
Region-specific reimbursement practices
Key market access considerations in ovarian cancer: United States
General reimbursement environment: United States
Key market access considerations in ovarian cancer: EU5
General reimbursement environment: EU5
Key market access considerations in ovarian cancer: Japan
General reimbursement environment: Japan
Appendix
Ovarian cancer bibliography
Marcos Fernu00e1ndez Alfara
Marcos Fernández Alfara, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Fernández has extensive experience in oncology, with a focus on novel immunotherapies for solid tumors. As part of his doctorate, he developed new strategies to boost immune responses against cancer cells. He obtained his master of science degree in cancer and stem cells from Utrecht University and his doctorate in biomedicine from the Institute for Research in Biomedicine at Barcelona University.
Charlotte Jago
Charlotte Jago, Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Jago is a pharmaceutical industry analyst with more than 18 years’ experience, preceded by 5 years of laboratory research in academia (Imperial College London) and industry (Celltech, now UCB). She wrote the flagship Cortellis Drugs to Watch reports in 2013, 2014, 2015, and 2019 and led the improvement in immuno-oncology coverage on the Cortellis Competitive Intelligence platform. She holds a Ph.D. in immunology, a first-class degree in pharmacology, and a postgraduate certificate in journalism.